Harvoni, created by Gilead Sciences, passed its Common Drug Review this week with the Canadian Drug Expert Committee (CDEC)’s Final Recommendation. The CDEC’s Final Recommendation advocates that Harvoni, ledipasvir/sofosbuvir, be listed for the treatment of chronic hepatitis C virus (CHC) genotype 1 infection in adults. It recommended three conditions for this.

The 3 conditions recommended by the Canadian Drug Expert Committee were:

• Liver fibrosis be at stage 2 or higher
• Treatment should be initiated by physicians experienced with treating chronic hep C
• A substantial reduction in price

For more details, go to: http://www.pacifichepc.org/hepctip/hep-c-tip-blog/